Viking Therapeutics (VKTX) to Present New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol at The Digital International Liver Congress 2020

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) will be presented at the Digital International Liver Congress™ 2020. The study results will be featured in an oral presentation at the annual meeting of the European Association for the Study of the Liver (EASL), being held virtually August 27-29, 2020.

As previously reported, the Phase 2 study of VK2089, Viking's novel liver-selective thyroid receptor beta agonist, successfully achieved both its primary and secondary efficacy endpoints, demonstrating median relative reductions in liver fat ranging from 53.8% to approximately 60%, and response rates of up to 100%, both of which represent unprecedented efficacy from an oral agent. The Digital International Liver Congress presentation will include new efficacy data measured at Week 16, four weeks following the completion of treatment. Additional new data will be reported on 12-week efficacy results stratified by baseline patient characteristics and known disease risk factors.

Details of the presentation are as follows:

VK2809, a Novel Liver-Directed Thyroid Receptor Agonist, Produces Durable Reductions in Liver Fat in Patients with Non-Alcoholic Fatty Liver Disease: Results of 4-Week Follow-Up Assessment from a 12-Week Phase 2 Randomized, Placebo-Controlled Trial

• Presentation Number: AS073
• Date/time: Friday, August 28, 2020, 6:00 – 6:15 a.m. EST
• Session: NAFLD – Pharmacological Therapy
• Presenter: Rohit Loomba, M.D., MHSc, Director, NAFLD Research Center, and Professor of Medicine, University of California at San Diego

Viking is currently evaluating VK2809 in the Phase 2b VOYAGE study in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.

You May Also Be Interested In

• Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
• Canopy Growth (CGC) Announces CBI Conversion to Exchangeable Shares, Appoints New Board
• 22nd Century Group (XXII) Announces Resignation of Sullivan and Mish from Board